

```
var drug_url = "ribavirin-drug";
```



Ribavirin (*Copegus, Rebetol, Ribasphere*)

- [Editor's Summary](#)
- [Prescribing Information](#)
- [Clinical Trials](#)
- [References](#)
- [Slide Deck](#)
- [Teaching Resources](#)

Table of Contents

- [Ribavirin Copegus, Rebetol, Ribasphere Editor's Summary](#)
- [Drug Summary](#)
- [Class and Mechanism](#)
- [Manufacturer for United States](#)
- [Cost and Medication Access](#)
- [Adverse Effects](#)
- [Key Drug Interactions](#)

Drug Summary

Ribavirin has been an integral component of hepatitis C therapy. When used with interferon or peginterferon, ribavirin significantly reduces relapse rates and significantly improves sustained virologic responses. Currently, ribavirin plays a significant role in the treatment of all hepatitis C genotypes. Dosing of ribavirin is somewhat complicated and includes fixed-dose and weight-based ribavirin, with dosing depending on the genotype and brand of ribavirin used. In addition, ribavirin can cause severe anemia and dose adjustment is required in some patients who develop anemia. Ribavirin will likely continue to play an important role in the treatment of hepatitis C, but eventually will likely be replaced by highly effective, better tolerated combinations of direct acting agents.

Class and Mechanism

Ribavirin is a purine nucleoside analog that has an incompletely understood mechanism of action against hepatitis C virus. Investigators have proposed four main potential sites of ribavirin action against hepatitis C virus: (1) augmentation of host T-cell immune clearance of HCV, (2) inhibition of the host enzyme inosine monophosphate dehydrogenase (IMPDH) that results in depleted pools of guanosine triphosphate, an essential substrate for viral RNA synthesis (3) direct inhibition of HCV

replication, and (4) induction of RNA virus mutagenesis that drives HCV to an abnormally high error rate.

Manufacturer for United States

Ribavirin is manufactured by multiple companies in the United States: *Copegus* ([Figure 1](#)) is produced by Genentech (member of the Roche group), *Rebetol* by Merck Sharp & Dome, a subsidiary of Merck & Co., Inc., and *Ribasphere* by Kadmon Pharmaceuticals (originally by Three Rivers Pharmaceuticals which was acquired by Kadmon Pharmaceuticals). In addition, several companies, including Sandoz ([Figure 3](#)) and Teva ([Figure 4](#)) pharmaceuticals, produce generic ribavirin.

Cost and Medication Access

The wholesale acquisition cost (WAC) for ribavirin is difficult to report, given the multiple brand and generic preparation and given the variable doses used with weight-based dosing. In general, the generic preparations are less expensive than the brand drugs. As a rough estimate, a 12-week course of generic ribavirin is in the range of \$550 to \$850. Accordingly, the ribavirin component of a 48-week treatment course costs approximately \$1100 to \$1700.

Rebetol Patient Assistance: For information regarding reimbursement support services for ribavirin (*Rebetol*), see the [ACT Program](#) website or call [866-363-6379](tel:866-363-6379). This is the same patient assistance program for peginterferon alfa-2b (*Pegintron*).

Copegus Patient Assistance: For information regarding coverage, reimbursement, and patient assistance for *Copegus*, visit the [Access Solutions](#) website or call [888-941-3331](tel:888-941-3331). This is the same patient assistance program for peginterferon alfa-2a (*Pegasys*).

Ribasphere, Ribapak Patient Assistance: For information regarding reimbursement support services for ribavirin (*Rebetol*), contact the Kadmon Enabling Your Success (K.E.Y.S.) Program at [888-668-3393](tel:888-668-3393).

Adverse Effects

Two potentially serious ribavirin-associated adverse effects are listed as black box warnings.

- **Hemolytic Anemia:** Ribavirin can cause a potentially severe hemolytic anemia. The hemolytic anemia can occur suddenly and can result in worsening of cardiac disease, even leading to myocardial infarction. The hemolytic anemia most often occurs within 1 to 2 weeks after starting therapy. Accordingly, patients should have a hematocrit and/or hemoglobin checked prior to starting therapy and at week 2 and 4 of therapy.
- **Birth Defects:** Ribavirin can cause significant teratogenic and embryocidal effects, including potential birth defects and fetal death. Ribavirin should not be used by women during pregnancy or in male partners of women who are pregnant. For women who will receive treatment with ribavirin, a documented negative pregnancy test is required immediately prior to starting ribavirin therapy and women should use two or more

forms of birth control and have monthly pregnancy testing during treatment and for 6 months thereafter. Further, pregnancy should be avoided for at least 6 months after completing ribavirin therapy (for females who have taken ribavirin and for females partners of males who have taken ribavirin).

Other less serious adverse effects have been observed with ribavirin, including fatigue, nausea, rash, and itching. To report suspected adverse reactions, contact (1) the ribavirin manufacturer or (2) the FDA at 1-800-FDA-1088.

Key Drug Interactions

For complete information on ribavirin-related drug interactions, see the [Drug Interactions section in the Ribavirin \(Copegus, Rebetol, Ribasphere\) Prescribing Information](#).
